Bradsher Neal C 4

What Happened

• Neal C. Bradsher, a director and reported 10% owner of Lineage Cell Therapeutics, Inc. (LCTX), received a grant of 125,000 derivative awards (described as options) on July 1, 2026. The Form 4 reports an acquisition price of $0.00 for the award and lists the transaction as a derivative grant (125,000 shares, $0 total).

Key Details

• Transaction date and price: July 1, 2026; 125,000 options/awards reported at $0.00.
• Transaction type: Award/Grant (derivative), filed on Form 4 with period of report 2026-07-01 and filing date 2026-07-02 (timely filing).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnotes of note:
  • F1: Vesting: options vest and become exercisable on the earlier of (a) July 1, 2027 or (b) the Issuer’s next annual meeting after the grant date, subject to continuous service.
  • F2: Grant was made as director compensation under the Issuer’s 2021 Equity Incentive Plan.
  • F3: The filing also states these options are currently exercisable (as reported).
• No late filing flag indicated in the provided data.

Context

• This was a compensation award (not an open-market purchase or sale). As a derivative grant, it does not represent an immediate purchase of shares; the filing indicates these are options/awards that may convert into shares under the plan’s terms. Because Bradsher is both a director and a 10% owner, the grant is part of insider compensation rather than a standalone market trade.